Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements...
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of...
INVESTIGATION ALERT: Halper Sadeh LLP Investigates VMW, TPTX, CTT, CTEK
NEW YORK, NY / ACCESSWIRE / June 9, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...